Stories

At the heart of Ipsen’s early discovery efforts is a question of fit—how a molecule interacts with a disease-relevant protein, and what that means for therapeutic potential. Alexis Cocozaki’s team focuses on that exact space, applying biophysical and structural biology techniques to evaluate and optimize new assets at the atomic level. 

Working in early development, I have the privilege to see the next generation of therapeutic science take shape – and few areas are more compelling than immuno-oncology (I-O). From first data points in the lab to breakthroughs in the clinic, it is clear that we are entering a new era with the potential to deliver transformative outcomes for patients.

Late-stage partnering is unforgiving — high-stakes, capital-intensive, and fiercely competitive. The cost of a poor partnership isn’t just financial; it’s the lost opportunity to advance a program that could have changed patient outcomes but didn’t get the right partner at the right moment.

For many people at Ipsen, the impact of their work becomes clear through patient stories, scientific breakthroughs, or moments shared with colleagues. For Emilie Manier, Senior Executive Assistant, that realization came in a much more unexpected situation: a dinner with friends. 

New in our A Life in Science series, we hear from Audrey Clapéron, Translational Biology Director, about the essential role of data in driving discovery forward. She shares how leading a team of pharmacologists and delivering high-quality evidence for clinical development keeps her motivated and close to the patients who may one day benefit.